Type II HyperlipidemiaPhase 2NCT00688896
Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia
A Phase 2 study testing JTT-705 600 mg and pravastatin 40 mg and JTT-705 300 mg and pravastatin 40 mg in people with Type II Hyperlipidemia, run by Shionogi Inc. at 1 site in Netherlands.
Trial summary
The purpose of this study is to evaluate the effect of two dose levels of JTT-705 when co-administered with pravastatin 40 mg on HDL-C and LDL-C and the inhibition rate of CETP activity and to document short term safety. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Type II Hyperlipidemia
- What is being tested?
- JTT-705 600 mg and pravastatin 40 mg and JTT-705 300 mg and pravastatin 40 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 155 participants
- Where
- 1 siteNetherlands
- Study dates
- Jun 2002to Mar 2004
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients having lipid values as indicated below:
- HDL-C less than 1.6 mmol/L (60 mg/dL)
- TG less than 4.5 mmol/L (400 mg/dL)
- LDL more than 4.0 mmol/L (160 mg/dL)
- Patients with CHD or CHD risk equivalent
- Male and females between 18 and 65 years of age (female patients must be post-menopausal, surgically sterile or using an acceptable form of contraception)
Who cannot join
- Body Mass Index of ≥ 35 kg/m2
- Females that are pregnant or breast-feeding, and females of child bearing potential who are not using an effective method of contraception
- Concomitant use of medications identified in the protocol
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia
The purpose of this study is to evaluate the effect of two dose levels of JTT-705 when co-administered with pravastatin 40 mg on HDL-C and LDL-C and the inhibition rate of CETP activity and to document short term safety.
- Conditions
- Type II Hyperlipidemia
- Being tested
- JTT-705 600 mg and pravastatin 40 mg, JTT-705 300 mg and pravastatin 40 mg, Placebo and pravastatin 40 mg
- Medical subject headings
- Hyperlipoproteinemia Type II
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
JTT-705 600 mg and pravastatin 40 mgDrug
- JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment
- Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
JTT-705 300 mg and pravastatin 40 mgDrug
- JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment
- Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
- Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
Placebo and pravastatin 40 mgDrug
- Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments
- Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | JTT-705 600 mg and pravastatin 40 mg Receives: Drug: JTT-705 600 mg and pravastatin 40 mg |
| 2 | Experimental | JTT-705 300 mg and pravastatin 40 mg Receives: Drug: JTT-705 300 mg and pravastatin 40 mg |
| 3 | Placebo comparator | Placebo and pravastatin 40 mg Receives: Drug: Placebo and pravastatin 40 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
% change from baseline in HDL-C; inhibition of CETP activity
Measured: 4-weeks
Secondary outcomes (2)
% change from baseline in LDL-C and TC/HDL-C
Measured: 4-weeks
Plasma concentration of JTT-705
Measured: 4-weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2008 (estimated)
- Study startJun 2002
- Primary completionApr 2003
- Study completionMar 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type II HyperlipidemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 155 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shionogi Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00688896
- Sponsor's protocol ID
- AT705-X-02-001
- Status last verified
- May 2008
- First submitted
- 29 May 2008
- Last updated
- 3 Jun 2008
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Jun 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia
- ClinicalTrials.gov ID
- NCT00688896
- Acronym / sponsor ID
- AT705-X-02-001
- Conditions
- Type II Hyperlipidemia
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 155 participants (actual)
- Lead sponsor
- Shionogi Inc.Industry (pharma, biotech, devices)
- Study start
- Jun 2002
- Primary completion
- Apr 2003 (actual)
- Study completion
- Mar 2004 (actual)
- First posted
- 3 Jun 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the effect of two dose levels of JTT-705 when co-administered with pravastatin 40 mg on HDL-C and LDL-C and the inhibition rate of CETP activity and to document short term safety.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: JTT-705 600 mg and pravastatin 40 mgJTT-705 600 mg and pravastatin 40 mg |
| 2 | Experimental | Drug: JTT-705 300 mg and pravastatin 40 mgJTT-705 300 mg and pravastatin 40 mg |
| 3 | Placebo comparator | Drug: Placebo and pravastatin 40 mgPlacebo and pravastatin 40 mg |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patients having lipid values as indicated below:
- HDL-C less than 1.6 mmol/L (60 mg/dL)
- TG less than 4.5 mmol/L (400 mg/dL)
- LDL more than 4.0 mmol/L (160 mg/dL)
- Patients with CHD or CHD risk equivalent
Key exclusion criteria (3 listed)
- Body Mass Index of ≥ 35 kg/m2
- Females that are pregnant or breast-feeding, and females of child bearing potential who are not using an effective method of contraception
- Concomitant use of medications identified in the protocol
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| JTT-705 600 mg and pravastatin 40 mg* JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment * Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime | Drug | 1 |
| JTT-705 300 mg and pravastatin 40 mg* JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment * Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments * Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime | Drug | 2 |
| Placebo and pravastatin 40 mg* Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments * Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime | Drug | 3 |
Primary outcome
% change from baseline in HDL-C; inhibition of CETP activity
Time frame: 4-weeks
2 secondary outcomes
% change from baseline in LDL-C and TC/HDL-C
Time frame: 4-weeks
Plasma concentration of JTT-705
Time frame: 4-weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jun 2008.
Related trials for Type II Hyperlipidemia
Active, not recruitingObservational study
Early Detection of Familial Hypercholesterolaemia in Pre-school Children ( CzeCH-IT)
Familial Hypercholesterolaemia
Not yet recruiting
Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3
Familial Hypercholesterolemia
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Not yet recruitingObservational study
An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia
Hypercholesterolaemia, Familial Hypercholesterolaemia
Active, not recruitingObservational study
Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing JTT-705 600 mg and pravastatin 40 mg and JTT-705 300 mg and pravastatin 40 mg in people with Type II Hyperlipidemia, run by Shionogi Inc. at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Jun 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
% change from baseline in HDL-C; inhibition of CETP activity (time frame: 4-weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2008.